Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage

Pharmacological Research

Volumn 57, Issue 5, 2008, Pages 325-331

  Lim, Ju Hee ^a   Kim, Kyeong Man ^a   Kim, Seong Who ^b   Hwang, Onyou ^b   Choi, Hyun Jin ^a  

^a Chonnam National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Bromocriptine; NQO1; Nrf2; Oxidative damage; Parkinson's disease; PI3K Akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BROMOCRIPTINE; DOPAMINE RECEPTOR; HYDROGEN PEROXIDE; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN NQO1; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CYTOPROTECTION; DOPAMINE AGONISTS; HYDROGEN PEROXIDE; NAD(P)H DEHYDROGENASE (QUINONE); NEURONS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PARKINSON DISEASE; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 44549085003     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.03.004     Document Type: Article

References (40)

1. de Lau L.M., and Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006) 525-535
2. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
3. Hastings T.G., and Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J Neural Transm Suppl 49 (1997) 103-110
4. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5 (2003) 165-176
5. Choi H.J., Kim S.W., Lee S.Y., and Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 86 (2003) 143-152
6. Joseph P., Longll D.J., Klein-Szanto A.J., and Jaiswal A.K. Role of NAD(P)H: quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmarcol 60 (2000) 207-214
7. Cavelier G., and Amzel L.M. Mechanism of NAD(P)H: quinine reductase: ab initio studies of reduced flavin. Proteins 43 (2001) 420-432
8. van Muiswinkel F.L., de Vos R.A., Bol J.G., Andringa G., Jansen Steur E.N., Ross D., et al. Expression of NAD(P)H: quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25 (2004) 1253-1262
9. Han J.M., Lee Y.J., Lee S.Y., Kim E.M., Moon Y., Kim H.W., et al. Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 321 (2007) 249-256
10. Venugopal R., and Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93 (1996) 14960-14965
11. Lee J.M., Shih A.Y., Murphy T.H., and Johnson J.A. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278 (2003) 37948-37956
12. Calkins M.J., Jakel R.J., Johnson D.A., Chan K., Kan Y.W., and Johnson J.A. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 102 (2005) 244-249
13. Shih A.Y., Li P., and Murphy T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25 (2005) 10321-10335
14. Radad K., Gille G., and Rausch W.D. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 57 (2005) 701-712
15. Takashima H., Tsujihata M., Kishikawa M., and Freed W.J. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 159 (1999) 98-104
16. Schapira A.H. Neuroprotection in PD-a role for dopamine agonists?. Neurology 61 (2003) S34-S42
17. Yoshikawa T., Minamiyama Y., Naito Y., and Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62 (1994) 1034-1038
18. Li M., Bermak J.C., Wang Z.W., and Zhou Q.Y. Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol 57 (2000) 446-452
19. Hwang O., Kim G., Jang Y.J., Kim S.W., Choi G., Choi H.J., et al. Synthetic phytoceramides induce apoptosis with higher potency than ceramides. Mol Pharmacol 59 (2001) 1249-1255
20. Lin Y.L., Ho I.C., Su P.F., and Lee T.C. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression. Toxicol Appl Pharmacol 214 (2006) 309-317
21. Paz M.A., Fluckiger R., Boak A., Kagan H.M., and Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 266 (1991) 689-692
22. Segura-Aguilar J., Metodiewa D., and Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381 (1998) 1-6
23. Hastings T.G., and Zigmond M.J. Identification of catecholprotein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 63 (1994) 1126-1132
24. Kang K.W., Lee S.J., Park J.W., and Kim S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 62 (2002) 1001-1010
25. Kitamura Y., Taniguchi T., Shimohama S., Akaike A., and Nomura Y. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 28 (2003) 1035-1040
26. Chae S.W., Bang Y.J., Kim K.-M., Lee K.Y., Kang B.Y., Kim E.M., et al. Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation. Biochem Biophys Res Commun 359 (2007) 735-741
27. Zafar K.S., Inayat-Hussain S.H., Siegel D., Bao A., Shieh B., and Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 166 (2006) 261-267
28. Beyer R.E., Segura-Aguilar J., Di Bernado S., Cavazzoni M., Fato R., and Fiorentini D. The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes. Mol Aspects Med 18 (1997) 15-23
29. Siegel D., Bolton E.M., Burr J.A., Liebler D.C., and Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 52 (1997) 300-305
30. Nair V.D., and Sealfon S.C. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem 278 (2003) 47053-47061
31. Nair V.D., Olanow C.W., and Sealfon S.C. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373 (2003) 25-32
32. Wang X., McCullough K.D., Franke T.F., and Holbrook N.J. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 275 (2000) 14624-14631
33. Papaiahgari S., Zhang Q., Kleeberger S.R., Cho H.Y., and Reddy S.P. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. Antioxid Redox Signal 8 (2006) 43-52
34. Hara H., Ohta M., Ohta K., Kuno S., and Adachi T. Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 119 (2003) 125-131
35. Le W.D., Jankovic J., Xie W., and Appel S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107 (2000) 1165-1173
36. Sethy V.H., Wu H., Oostveen J.A., and Hall E.D. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 854 (1997) 181-186
37. Marvanova M., and Nichols C.D. Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31 (2007) 127-137
38. Hara H., Ohta M., and Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 84 (2006) 860-866
39. Pothos E.N., Przedborski S., Davila V., Schmitz Y., and Sulzer D. D2-Like dopamine autoreceptor activation reduces quantal size in PC12 cells. J Neurosci 18 (1998) 5575-5585
40. Wang H., Yuan G., Prabhakar N.R., Boswell M., and Katz D.M. Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling. J Neurochem 96 (2006) 694-705